Hansa Biopharma ROCE 2024

Hansa Biopharma Aktienanalyse

What does Hansa Biopharma do?

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Hansa Biopharma's Return on Capital Employed (ROCE)

Hansa Biopharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Hansa Biopharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Hansa Biopharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Hansa Biopharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Hansa Biopharma Stock

What is the ROCE (Return on Capital Employed) of Hansa Biopharma this year?

The ROCE of Hansa Biopharma is 4.71 undefined this year.

How has the ROCE (Return on Capital Employed) of Hansa Biopharma developed compared to the previous year?

The ROCE of Hansa Biopharma has increased by -593.19% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Hansa Biopharma?

A high Return on Capital Employed (ROCE) indicates that Hansa Biopharma has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Hansa Biopharma?

A low ROCE (Return on Capital Employed) can indicate that Hansa Biopharma has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Hansa Biopharma impact the company?

An increase in the ROCE of Hansa Biopharma can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Hansa Biopharma affect the company?

A decrease in ROCE of Hansa Biopharma can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Hansa Biopharma?

Some factors that can affect Hansa Biopharma's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Hansa Biopharma so important for investors?

The ROCE of Hansa Biopharma is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Hansa Biopharma take to improve the ROCE?

To improve the ROCE, Hansa Biopharma can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Hansa Biopharma pay?

Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.

What is the dividend yield of Hansa Biopharma?

The current dividend yield of Hansa Biopharma is .

When does Hansa Biopharma pay dividends?

Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hansa Biopharma?

Hansa Biopharma paid dividends every year for the past 0 years.

What is the dividend of Hansa Biopharma?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hansa Biopharma located?

Hansa Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansa Biopharma from 6/19/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Hansa Biopharma pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Hansa Biopharma in the year 2023?

In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.

In which currency does Hansa Biopharma pay out the dividend?

The dividends of Hansa Biopharma are distributed in SEK.